Phase II Panitumumab-IRDye800 in Head & Neck Cancer

Eligibility Criteria

• 1. Biopsy confirmed diagnosis of squamous cell carcinoma of the head and neck
• 2. Diagnosis of any T stage, any subsite within the head and neck that are scheduled to undergo surgical resection. Patients with recurrent disease or a new primary will be allowed.
• 3. Planned standard of care surgery with curative intent for squamous cell carcinoma
• 4. Male or female patients age ≥ 18 years
• 5. Have life expectancy of more than 12 weeks
• 6. Karnofsky performance status of at least 70% or ECOG/Zubrod level 1
• 7. Have acceptable hematologic status, coagulation status, kidney function, and liver function including the following clinical results:
• 1. Hemoglobin ≥ 9 gm/dL
• 2. Absolute Neutrophil Count ≥ 1500
• 3. White Blood Cell count \> 3000/mm3
• 4. Platelet count ≥ 100,000/mm3
• 5. Serum creatinine ≤ 1.5 times upper reference range
• 1. Received an investigational drug within 30 days prior to first dose of panitumumab-IRDye800
• 2. Had within 6 months prior to enrollment: MI, CVA, or uncontrolled CHF
• 3. History of infusion reactions to any monoclonal antibody therapies
• 4. Women who are pregnant or breast-feeding
• 5. Evidence of QT prolongation on pretreatment ECG (greater than 440 ms in males or greater than 450 ms in females)
• 6. Magnesium or potassium lower than the normal institutional values
• 7. Patients receiving Class IA (quinidine, procanamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents
• 8. Patients with a history or evidence of interstitial pneumonitis or pulmonary fibrosis
• 9. TSH \> 13 micro International Units/mL